13F Holdings
中文EN

TRAW Traws Pharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1130598 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,159.3%
TTM net income YoY90.5%
TTM EPS YoY95.1%
Revenue 3-yr CAGR132.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-554.6%
Net margin-467.6%
FCF margin—
EBITDA margin-554.0%

Returns

ROE-1,059.6%
ROA-124.5%
ROIC (approx.)—
Asset turnover0.27x

Leverage & solvency

Liabilities / assets63.5%
Debt / equity0.00x
Current ratio1.22x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.46x
Accruals ratio57.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.79M$226,000$226,000$226,000$226,000
R&D expense$12.14M$12.85M$11.43M$11.41M$7.30M
SG&A expense$8.52M$12.29M$9.09M$8.45M$9.43M
Operating income-$17.88M-$142.37M-$20.30M-$19.63M-$16.50M
Pretax income$9.17M-$166.53M-$18.95M-$18.96M-$16.16M
Net income$9.17M-$166.52M-$18.95M-$18.96M-$16.16M
EBITDA-$17.81M-$142.36M-$20.28M-$19.61M-$16.48M
EPS (basic)0.83-35.21-22.57-0.91-0.96
EPS (diluted)0.82-35.21-22.57-0.91-0.96
Weighted avg. shares (diluted)8.38M1.55M839,55420.91M16.83M
Balance sheet
Cash & equivalents$3.82M$21.34M$20.82M$38.76M$55.07M
Receivables$3.79M$1.76M$18,000$29,000$28,000
Current assets$7.98M$24.95M$22.66M$39.35M$55.43M
PP&E, net$7,000$10,000$22,000$24,000$38,000
Intangibles$2.53M————
Total assets$10.62M$24.96M$22.68M$39.37M$55.48M
Current liabilities$11.15M$11.53M$9.22M$8.05M$6.12M
Total liabilities$11.25M$56.59M$12.01M$11.06M$9.36M
Shareholders' equity-$629,000-$31.63M$10.67M$28.31M$46.12M
Shares outstanding9.07M3.65M840,25120.93M20.90M
Cash flow statement
Operating cash flow-$18.18M-$29.79M-$17.93M-$16.29M-$19.49M
Capital expenditure$2.58M$3.65M$14,000——
Free cash flow-$20.77M-$33.44M-$17.95M——
Investing cash flow-$2.58M-$3.65M-$14,000——
Financing cash flow$3.20M$33.98M——$55.56M
Depreciation & amortization$61,000$12,000$16,000$14,000$14,000
Stock-based compensation$728,000$1.39M$1.30M$1.17M$576,000

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.